CELLMID LIMITED (CDY)

name changed to Anagenics Limited

The suspension of trading in the securities of Cellmid Limited will be lifted immediately, following the release by CDY, announcements responding to a media article and regarding the testing results conducted by the Peter Doherty Institute for Infection and Immunity.

The company reports on results of the Doherty Institute testing.

Cellmid signed an Introducer Agreement with Emergence Technology Pty Ltd securing access to additional SARS-CoV-2 tests for its customers. Emergence is responsible for the supply of the Tests. The Tests are available to Emergence globally. The Agreement allows for the payment of a Commission to Cellmid in relation to sales on introductions it makes to potential customers.

The company releases the Results of Meeting.

The company releases its General Meeting Presentation.

Considering the increased media coverage and confusion in relation to the SARSCoV-2 POCTs Cellmid has decided that, pursuant to ASX Listing Rule 17.2, it would be prudent to request an extension of the voluntary suspension of its securities until the Doherty Review results are received.

The Board of Cellmid Limited have made the decision that, in the interests of safety, physical attendance by shareholders will not be permitted at the upcoming General Meeting being held at 2pm (AEST) on Thursday, 21 May 2020. Cellmid are making the meeting available to shareholders via zoom and shareholders wishing to attend in this manner are asked to register their interest by sending an email to egm@cellmid.com.au. Requests to attend the meeting by zoom must be received by 7pm (AEST) on Tuesday, 19 May 2020.

The securities of Cellmid Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDY, pending the release of an announcement in response to a media article.

The suspension of trading in the securities of Cellmid Limited will be lifted immediately, following the release by CDY of an announcement regarding a capital raising.

The company issues a notice of Proposed issue of Securities - CDY.

Cellmid has raised $6 million (before costs) via a share placement from institutional and sophisticated investors. Existing shareholders will have the opportunity to participate on the same terms via a Share Purchase Plan targeting an additional $1.0 million. Proceeds raised under the offer will be used to fund the roll out of the Wondfo SARS-V-2 diagnostic test.

The company issues a response to ASX Query Letter.

The securities of Cellmid Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDY, pending the release of an announcement regarding a proposed capital raising.

The suspension of trading in the securities of Cellmid Limited will be lifted from the commencement of trading on Monday, 30 March 2020, following the release by CDY of an announcement regarding a new material supply agreement.

Sales of the Company's consumer health products in Australia and Japan have been moderately impacted over the past few weeks. Australia, representing around 23% of sales historically, performed well until the end of February, however, the product launch planned for March in Priceline has been delayed, which will start effecting sales from April onwards locally. Operational expenditure of the Company is carefully monitored and reduced where sensible. The Company has been exploring new product lines that can bring additional revenues in the near term. Research and development activities have not been affected to date. The Company has determined that it is prudent to withdraw its previous guidance that it will achieve operational profitability for its consumer business by the end of FY2020, and will separate Lyramid into a wholly independent entity backed by independent funding and/or a partnership with a biopharmaceutical company by the end of 2020.

Cellmid signs a supply agreement for a COVID-19 rapid diagnostic test with the Australian agent of a Therapeutic Good Administration certified Chinese manufacturer. The COVID-19 rapid diagnostic test is CE Marked, TGA and NMPA (National Medical Products Administration) approved . The test uses virus specific IgG/IgM detection method returning results quickly, and no requirement for PCR (Polymerase Chain Reaction) equipment . The test is available immediately and is suitable as a bedside test, can be used in hospitals, nursing homes, schools, remote areas and by corporates when administered by healthcare professionals as well as in pathology labs.

The securities of Cellmid Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDY, pending the release of an announcement regarding a new material supply agreement.

we understand that on or about this date the company consolidated its shares 1 for 20

The securities of Cellmid Limited will be reinstated to official quotation immediately today, Tuesday 1 November 2016, in accordance with listing rule 17.7, following lodgement of an announcement in relation to the completion of a capital raising by the Company.

The company received commitments totalling $3 million, for new fully paid shares in the Company at 3 cents per Placement Share (the Placement). The Placement was supported by new institutional and sophisticated investors as well as existing shareholders. The Company will use the funds raised to launch the evolis® FGF5 inhibitor hair growth products in the US market.

The company lodges its Appendix 4C - quarterly report.

The securities of Cellmid Limited will be suspended from quotation immediately, at the request of the Company in accordance with Listing Rule 17.2.

name changed from Medical Therapies Limited